In a significant move towards bolstering its autoimmune and gastroenterology disease portfolio, Sanofi has entered into a strategic collaboration with Teva Pharmaceuticals to co-develop and co-commercialise Teva’s novel anti-TL1A therapy, TEV’574, for the treatment of ulcerative colitis and Crohn's disease, in a deal that could be worth up to US$1.5 B. This collaboration may represent a significant stride towards innovative therapies and could highlight the potential of TEV’574 to become a best-in-class option for people living with irritable bowel syndrome.